Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial

Overview of attention for article published in BMC Medicine, November 2020

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (62nd percentile)

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 35 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 7 publications that cite this research output.

7

The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.

Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial

Article in Trials (March 2024)

A Comprehensive Review on Long vs. Short Regimens in Multidrug-Resistant Tuberculosis (MDR-TB) Under Programmatic Management of Drug-Resistant Tuberculosis (PMDT)

Article in Cureus (January 2024)

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

Article in The Lancet (November 2022)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.